N
Nivagen Pharmaceuticals
Company engaged in the development, acquisition, and sales of generic prescription drugs and over-the-counter products for the north american market
About Nivagen Pharmaceuticals
Nivagen Pharmaceuticals is engaged in the development, acquisition, and sales of generic prescription drugs and over-the-counter (OTC) products for the North American market. The company focuses on leveraging global partnerships with FDA-approved manufacturing facilities to deliver high-quality products at affordable prices. Nivagen's business model includes identifying and utilizing the world's best and most economical Contract Research Organizations (CROs) and Contract Research and Manufacturing Services (CRAMs) to develop and manufacture niche products. The company serves a diverse range of clients, including small FDA-qualified manufacturers looking to launch their products in the U.S. market. Nivagen's core strengths lie in its ability to launch new generic products and its highly skilled sales and marketing team. The company operates in a market where approximately $60 billion is spent on generic prescriptions annually, with over $120 billion worth of products expected to come off patent protection in the next decade. Nivagen generates revenue through product development, co-development, acquisition, in-licensing, and providing sales and marketing services. The company is actively seeking partnerships with CROs and CRAMs for co-development and is also acquiring existing products to expand its portfolio.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Employees
- 152
- Open positions
- 16
- Dealroom signal
- 58.4/100
- Industry
- Health, Marketing
- Sub-industry
- Pharmaceutical
- Sector
- Supply Chain Management, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
News
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Jan 2026 | $0 | — | PAI Pharma | ↗ |
| GROWTH EQUITY VC✓Equity / VC | May 2020 | $16M | — | Telegraph Hill Partners | ↗ |
Growth signals
Latest recorded traffic for Nivagen Pharmaceuticals is 6.4K monthly website visits, up 10.3% over the last three months. Nivagen Pharmaceuticals's team grew 40.7% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Nivagen Pharmaceuticals in the Rancho Cordova ecosystem
The Nivagen Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
Telegraph Hill Partners
Other known investors2 additional known investors
PAI Pharma
Corbel Capital Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Nivagen Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Nivagen Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.






